In the continuing fight against the novel Coronavirus, researchers have now identified a drug with the potential to provide treatment for Covid-19 close to a year after it turned into a pandemic.
The study, published in the journal Cells, found that the approved protease inhibitor aprotinin displayed activity against SARS-CoV-2, the coronavirus that causes Covid-19, in concentrations that are achieved in patients.
According to the researchers, aprotinin aerosols are approved in Russia for the treatment of influenza and could be readily tested for the treatment of Covid-19.
Aprotinin inhibits the entry of SARS-CoV-2 into host cells and may compensate for the loss of host cell protease inhibitors that are downregulated upon SARS-CoV-2 infection.
"The aprotinin aerosol has been reported to be tolerated extremely well in influenza patients. Hence, it may have a particular potential to prevent severe Covid-19 disease when applied early after diagnosis," said study author Martin Michaelis from the University of Kent in the UK.
"Aprotinin has previously been shown to inhibit TMPRSS2 gene and has been suggested as a treatment option for influenza viruses and coronaviruses. Herein, we investigated the effects of aprotinin against SARS-CoV-2," Michaelis added.
The findings showed that aprotinin displayed anti-SARS-CoV-2 activity in different cell types (Caco2, Calu-3, and primary bronchial epithelial cell air-liquid interface cultures) and against four virus isolates.
"An approved aprotinin aerosol may have the potential for the early local control of SARS-CoV-2 replication and the prevention of Covid-19 progression to a severe, systemic disease," the study authors noted.
(This story has been published from a wire agency feed without modifications to the text. Only the headline has been changed.)
As you are no doubt aware, Swarajya is a media product that is directly dependent on support from its readers in the form of subscriptions. We do not have the muscle and backing of a large media conglomerate nor are we playing for the large advertisement sweep-stake.
Our business model is you and your subscription. And in challenging times like these, we need your support now more than ever.
We deliver over 10 - 15 high quality articles with expert insights and views. From 7AM in the morning to 10PM late night we operate to ensure you, the reader, get to see what is just right.
Becoming a Patron or a subscriber for as little as Rs 1200/year is the best way you can support our efforts.